SCHEMBL10246565

SCHEMBL10246565

CC(C)(C)NCC1CCN(CCO)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNAI3 P08754 1/20 0.38
GNAO1 P09471 1/20 0.38
GNAI1 P63096 1/20 0.38
SLC18A3 Q16572 1/20 0.38
CACNA1I Q9P0X4 10/20 0.37
KCNH2 Q12809 7/20 0.37
CACNA1H O95180 1/20 0.36
CYP2D6 P10635 1/20 0.36
PKM P14618 1/20 0.35
KMT2A Q03164 1/20 0.35
CARM1 Q86X55 1/20 0.35
PRMT6 Q96LA8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
SLC2A1 P11166 1/20 0.34
EPHX1 P07099 1/20 0.34
EPHX2 P34913 1/20 0.34
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14768720 0.82 GNAI3 (0.38) GNAI3GNAO1GNAI1CACNA1IKCNH2
SCHEMBL21214167 0.82 GNAI3 (0.51) GNAI3GNAO1GNAI1CACNA1IKCNH2
SCHEMBL23919190 0.82 CACNA1I (0.49) GNAI3GNAO1GNAI1CACNA1IKCNH2
SCHEMBL14614920 0.81 GNAO1 (0.47) GNAI3GNAO1GNAI1KCNH2EPHX1
SCHEMBL22544374 0.79 L3MBTL1 (0.51) GNAI3GNAO1GNAI1SLC18A3PKM
SCHEMBL10245112 0.79 EPHX1 (0.41) GNAI3GNAO1GNAI1CACNA1IKCNH2
SCHEMBL4569282 0.79 NCF1 (0.46) GNAI3GNAO1GNAI1
SCHEMBL19958952 0.78 KCNH2 (0.52) GNAI3GNAO1GNAI1CACNA1IKCNH2
SCHEMBL16745494 0.78 ACHE (0.41)
SCHEMBL28004439 0.78 GNAI3 (0.46) GNAI3GNAO1GNAI1SLC18A3PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 GNAI3 1338/4885GNAO1 1807/4885GNAI1 955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.